Análisis del impacto presupuestario de alemtuzumab como terapia de segunda línea, en comparación con natalizumab y fingolimod, en pacientes previamente tratados con interferón beta 1b, diagnosticados con esclerosis múltiple remitente recurrente activa, tratados en la caja costarricense del seguro social
Aim: To assess the budget impact of the introduction of alemtuzumab in second-line treatment of active relapsing remitting multiple sclerosis (RRMS) patients, previously treated with interferon beta 1b, compared with natalizumab and fingolimod, from the Costa Rican Social Security (C.C.S.S.) perspec...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2019-03-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | https://doi.org/10.1177/2284240319833287 |